Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

PCI Announces Expansion of Packaging Capacity

Published: Friday, March 14, 2014
Last Updated: Friday, March 14, 2014
Bookmark and Share
PCI’s packaging site adds packaging space to accommodate business growth.

Packaging Coordinators, Inc. (PCI) has announced the completion of the planned expansion of its packaging facilities in Rockford, IL.

The Rockford site is one of three locations in the United States, and the facilities expansion in Rockford was designed to accommodate continued business development in its contract packaging services.

PCI converted underutilized space to further support its expanding packaging operations, adding 20,000 square feet for secondary and tertiary packaging. The additional production capacity will enable continued growth in operations such as cartoning, overwrapping, heat seal carding and compliance prompting packaging, as well as supporting packaging for biotech delivery forms such as secondary packaging for injectable vials, syringes, devices, and transdermal products. The packaging operations support both commercial operations as well as large-scale clinical studies.

In addition to packaging of commercial medicines, PCI provides clinical packaging services for investigational medicines at the Rockford location supported by on-site Storage and Distribution Services, facilitating global logistics for clinical studies.

In December 2013 PCI has announced the groundbreaking of a new 93,000 square foot Storage and Distribution site for investigational medicines, currently slated to be in operation in August of this year.

The clinical services expansion complements investments in PCI’s UK operations, most recently construction of a Storage and Distribution facility near Cardiff, Wales.

“The facilities expansion we have undertaken in Rockford is the latest in a series of investments we have made to enable continued growth and at the same time continue to provide our customers the extraordinary service they have come to expect from PCI,” states Bill Mitchell, President and Chief Executive Officer at PCI. “We are committed to providing an unparalleled customer experience with our clinical and commercial services, and those services require world class facilities. We are very excited about what these investments bring to our expanding business and our ability to support our clients.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

PCI Announces Opening of North American Clinical Facility
PCI opens North American storage and distribution facility for investigational medicinal products.
Thursday, October 16, 2014
PCI Announces Acquisition of Biotec
Acquisition expands clinical trial and cold chain services.
Friday, September 26, 2014
Scientific News
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Recruitment of First Patient in Clinical Study
Company has announced recruitment of first patient in clinical study assessing Visco-ease with Beatson Cancer Centre for the treatment of RIX.
Fighting Prostate Cancer
Identifying the most promising compounds which can be used as medications for prostate cancer.
Chi-Med Initiates Sulfatinib Phase III Registration Study
Company has initiated SANET-p, a Phase III registration trial of sulfatinib with pancreatic neuroendocrine tumors (“NETs”).
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!